Background

Cell-free DNA (cfDNA) fragmentomics has emerged as a minimally invasive window into tissue turnover and epigenetic state Cell-free DNA methylation patterns in aging and inflammaging. Recent work shows that cfDNA methylation patterns correlate with inflammaging and that fragment size distributions shift with age, reflecting altered nucleosome protection and apoptotic versus necrotic cell death Fragment size distribution shifts with age Apoptotic versus necrotic cfDNA fragmentation.

Hypothesis

We propose that the methylation density of nucleosome‑protected cfDNA fragments (140–180 bp) directly reports the burden of senescent cells that have undergone mitochondrial DNA (mtDNA) release, and that this metric predicts systemic inflammaging independent of total cfDNA concentration.

Mechanistic Rationale

1. Senescent cells exhibit chromatin relaxation at specific loci (e.g., p16^INK4a, SASP genes) leading to increased susceptibility of those regions to nucleosome‑level cleavage during apoptosis‑like DNA fragmentation.
2. Concurrently, senescent cells release oxidized mtDNA into the cytosol, which is subsequently packaged into extracellular vesicles and lysed, contributing a distinct, hypomethylated cfDNA pool enriched for mitochondrial sequences.
3. The combination of nuclear chromatin changes and mtDNA release yields cfDNA fragments that are (i) protected by nucleosomes (hence 140–180 bp) and (ii) bear a methylation signature reflecting the original senescent chromatin state (hypomethylated at SASP promoters, hypermethylated at lamin‑associated domains).
4. Because this senescence‑derived cfDNA resists rapid clearance (due to nucleosome protection and association with extracellular vesicles), its relative abundance in plasma integrates over the senescent cell burden and drives inflammaging via cGAS‑STING sensing of mtDNA and TLR9 activation by hypomethylated CpG motifs.

Testable Predictions

• Prediction 1: In cross‑sectional human plasma, the proportion of 140–180 bp cfDNA reads mapped to SASP‑associated nuclear loci will positively correlate with plasma IL‑6, TNF‑α, and circulating mtDNA levels, after adjusting for total cfDNA concentration.
• Prediction 2: Experimental clearance of senescent cells (e.g., via dasatinib + quercetin) in aged mice will reduce the methylation‑weighted 140–180 bp cfDNA fraction and concomitantly lower inflammaging biomarkers.
• Prediction 3: In vitro induction of senescence (irradiation, oncogene expression) will increase the release of nucleosome‑protected cfDNA carrying a methylation pattern distinct from that of apoptotic neutrophils or necrotic hepatocytes, detectable by size‑selected bisulfite sequencing.

Experimental Design

1. Human cohort: Collect plasma from 150 participants aged 30–90 y. Perform size‑selection (140–180 bp vs. <100 bp vs. >200 bp) followed by bisulfite sequencing. Quantify methylation at a curated panel of 20 SASP‑linked CpGs and 10 mitochondrial D‑loop sites. Correlate with serum cytokines and cell‑free mtDNA qPCR.
2. Intervention study: Treat aged (24‑month) mice with senolytic cocktail or vehicle for 4 weeks. Repeat cfDNA size‑fractionation and methylation profiling; assess SASP expression in tissues via RNA‑seq.
3. In vitro validation: Induce senescence in human fibroblasts; collect culture supernatant at 0, 24, 48 h; isolate cfDNA fractions; perform methyl‑C‑seq and compare to apoptosis (staurosporine) and necrosis (H₂O₂) controls.

Potential Confounders

• Variations in plasma collection (EDTA vs. citrate) affecting cfDNA integrity.
• Contribution from non‑senescent apoptotic lymphocytes; controlled by leukocyte‑specific methylation markers.
• Heterogeneity in extracellular vesicle uptake; mitigated by vesicle depletion controls.

Implications

If validated, the methylation‑weighted nucleosome‑protected cfDNA fraction could serve as a dynamic, tissue‑agnostic biomarker of senescent cell load, enabling longitudinal monitoring of senotherapeutic efficacy and providing a mechanistic link between chromatin alterations, mtDNA release, and inflammaging.